Fibrin formation by staphylothrombin facilitates staphylococcus aureus-induced platelet aggregation

Thrombosis and Haemostasis

Volumn 107, Issue 6, 2012, Pages 1107-1121

  Vanassche, Thomas ^a   Kauskot, Alexandre ^a   Verhaegen, Jan ^b   Peetermans, Willy E ^b   van Ryn, Joanne ^c   Schneewind, Olaf ^d   Hoylaerts, Marc F ^a   Verhamme, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Infective endocarditis; Platelet activation; Staphylococcus aureus; Staphylothrombin; Thrombin

Indexed keywords

ADENOSINE TRIPHOSPHATE; BACTERIAL ENZYME; DABIGATRAN; FIBRIN; FIBRINOGEN RECEPTOR; HIRUDIN; IMMUNOGLOBULIN G; PROSTAGLANDIN E2; PROTHROMBIN; STAPHYLOCOCCAL SERINE PROTEINASE; STAPHYLOTHROMBIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING TEST; FIBRIN FORMATION; FLUORESCENCE MICROSCOPY; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; NORMAL HUMAN; PRIORITY JOURNAL; SHEAR STRESS; STAPHYLOCOCCUS AUREUS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE RICH PLASMA;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD PLATELETS; COAGULASE; FIBRIN; HIRUDINS; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; MUTATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; RECEPTORS, IGG; STAPHYLOCOCCUS AUREUS; THROMBIN; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 84861734593     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-12-0891     Document Type: Article

References (42)

1. Cox D, Kerrigan SW, Watson S P. Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011; 9: 1097-1107.
2. Verschoor A, Neuenhahn M, Navarini AA, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8alpha(+) dendritic cells depends on glyco-protein GPIb and complement C3. Nat Immunol 2011; 12: 1194-1201.
3. Moreillon P, Que YA, Bayer AS. Pathogenesis of streptococcal and staphylococcal endocarditis. Infect Dis Clin North Am 2002;16: 297-318.
4. Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococ-cus aureus. J Clin Invest 2003; 112: 222-233.
5. Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 1999; 99: 2791-2797.
6. Kerrigan SW, Cox D. Platelet-bacterial interactions. Cell Mol Life Sci 2010; 67: 513-523.
7. Kerrigan SW, Clarke N, Loughman A, et al. Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arte-rioscler Thromb Vasc Biol 2008; 28: 335-340.
8. Miajlovic H, Loughman A, Brennan M, et al. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphy-lococcus aureus clumping factor B. Infect Immun 2007; 75: 3335-3343.
9. Fitzgerald JR, Loughman A, Keane F, et al. Fibronectin-binding proteins of Sta-phylococcus aureus mediate activation of human platelets via fibrinogen and fi-bronectin bridges to integrin GPIIb/IIIa and IgG binding to the FcgammaRIIa receptor. Mol Microbiol 2006; 59: 212-230.
10. Loughman A, Fitzgerald JR, Brennan M P, et al. Roles for fibrinogen, immunoglo-bulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57: 804-818.
11. Niemann S, Spehr N, Van Aken H, et al. Soluble fibrin is the main mediator of Sta-phylococcus aureus adhesion to platelets. Circulation 2004; 110: 193-200.
12. Heilmann C, Niemann S, Sinha B, et al. Staphylococcus aureus fibronectin-bind-ing protein (FnBP)-mediated adherence to platelets, and aggregation of platelets induced by FnBPA but not by FnBPB. J Infect Dis 2004; 190: 321-329.
13. O'Brien L, Kerrigan SW, Kaw G, et al. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 2002; 44: 1033-1044.
14. Bayer AS, Sullam PM, Ramos M, et al. Staphylococcus aureus induces platelet aggregation via a fibrinogen-dependent mechanism which is independent of principal platelet glycoprotein IIb/IIIa fibrinogen-binding domains. Infect Immun 1995; 63: 3634-3641.
15. Shannon O, Flock JI. Extracellular fibrinogen binding protein, Efb, from Staphy-lococcus aureus binds to platelets and inhibits platelet aggregation. Thromb Hae-most 2004; 91: 779-789.
16. Shannon O, Uekotter A, Flock JI. Extracellular fibrinogen binding protein, Efb, from Staphylococcus aureus as an antiplatelet agent in vivo. Thromb Haemost 2005; 93: 927-931.
17. Loughman A, Fitzgerald JR, Brennan M P, et al. Roles for fibrinogen, immunoglo-bulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol 2005; 57: 804-818.
18. Friedrich R, Panizzi P, Fuentes-Prior P, et al. Staphylocoagulase is a prototype for the mechanism of cofactor-induced zymogen activation. Nature 2003; 425: 535-539.
19. Kroh HK, Panizzi P, Bock PE. Von Willebrand factor-binding protein is a hyster-etic conformational activator of prothrombin. Proc Natl Acad Sci USA 2009; 106: 7786-7791.
20. Sawai T, Tomono K, Yanagihara K, et al. Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphy-lococcus aureus enmeshed in agar beads. Infect Immun 1997; 65: 466-471.
21. McAdow M, Kim HK, Dedent AC, et al. Preventing Staphylococcus aureus Sepsis through the Inhibition of Its Agglutination in Blood. PLoS Pathog 2011; 7: e1002307.
22. Cheng AG, McAdow M, Kim HK, et al. Contribution of coagulases towards Sta-phylococcus aureus disease and protective immunity. PLoS Pathog 2010; 6: e1001036.
23. Vanassche T, Verhaegen J, Peetermans WE, et al. Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence. J Thromb Haemost 2011; 9: 2436-2446.
24. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
25. Vanassche T, Verhaegen J, Peetermans WE, et al. Dabigatran inhibits Staphylococ-cus aureus coagulase activity. J Clin Microbiol 2010; 48: 4248-4250.
26. Panizzi P, Nahrendorf M, Figueiredo JL, et al. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 2011; 17: 1142-1146.
27. Yeaman MR, Puentes SM, Norman DC, et al. Partial characterization and staphy-locidal activity of thrombin-induced platelet microbicidal protein. Infect Immun 1992; 60: 1202-1209.
28. Yeaman MR, Sullam PM, Dazin PF, et al. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect Immun 1994; 62: 3416-3423.
29. Xiong YQ, Bayer AS, Yeaman MR. Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins. J Infect Dis 2002; 185: 348-356.
30. Mercier RC, Dietz RM, Mazzola JL, et al. Beneficial influence of platelets on antibiotic effi cacy in an in v it ro mod e l of St aphyloco ccus aureu s -induced endoca rdi-tis. Antimicrob Agents Chemother 2004; 48: 2551-2557.
31. Dhawan VK, Yeaman MR, Bayer AS. Influence of in vitro susceptibility phenotype against thrombin-induced platelet microbicidal protein on treatment and pro-phylaxis outcomes of experimental Staphylococcus aureus endocarditis. J Infect Dis 1999; 180: 1561-1568.
32. Fowler VG, Jr., McIntyre LM, Yeaman MR, et al. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of Staphylococcus aureus from endocarditis patients correlates with an intravascular device source. J Infect Dis 2000; 182: 1251-1254.
33. Kupferwasser LI, Yeaman MR, Shapiro SM, et al. In vitro susceptibility to throm-bin-induced platelet microbicidal protein is associated with reduced disease progression and complication rates in experimental Staphylococcus aureus endocarditis: microbiological, histopathologic, and echocardiographic analyses. Circulation 2002; 105: 746-752.
34. Jarvis GE, Atkinson BT, Frampton J, et al. Thrombin-induced conversion of fibri-nogen to fibrin results in rapid platelet trapping which is not dependent on platelet activation or GPIb. Br J Pharmacol 2003; 138: 574-583.
35. Herrmann M, Lai QJ, Albrecht RM, et al. Adhesion of Staphylococcus aureus to surface-bound platelets: role of fibrinogen/fibrin and platelet integrins. J Infect Dis 1993; 167: 312-322.
36. Jirouskova M, Dyr JE, Suttnar J, et al. Platelet adhesion to fibrinogen, fibrin monomer, and fibrin protofibrils in flowing blood -- the effect of fibrinogen immobilization and fibrin formation. Thromb Haemost 1997; 78: 1125-1131.
37. Miajlovic H, Loughman A, Brennan M, et al. Both complement- and fibrinogen-dependent mechanisms contribute to platelet aggregation mediated by Staphy-lococcus aureus clumping factor B. Infect Immun 2007; 75: 3335-3343.
38. George N P, Wei Q, Shin PK, et al. Staphylococcus aureus adhesion via Spa, ClfA, and SdrCDE to immobilized platelets demonstrates shear-dependent behavior. Arterioscler Thromb Vasc Biol 2006; 26: 2394-2400.
39. Sjobring U, Ringdahl U, Ruggeri ZM. Induction of platelet thrombi by bacteria and antibodies. Blood 2002; 100: 4470-4477.
40. Anderson CL, Chacko GW, Osborne JM, et al. The Fc receptor for immunoglobu-lin G (Fc gamma RII) on human platelets. Semin Thromb Hemost 1995; 21: 1-9.
41. Dryla A, Prustomersky S, Gelbmann D, et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005; 12: 387-398.
42. Vanassche T, Peetermans WE, Herregods MC, et al. Anti-thrombotic therapy in infective endocarditis. Expert Rev Cardiovasc Ther 2011; 9: 1203-1219.